CA2548038A1 - Traitement de troubles inflammatoires de l'epithelium au moyen de 2,3-benzodiazepines en faible dose - Google Patents

Traitement de troubles inflammatoires de l'epithelium au moyen de 2,3-benzodiazepines en faible dose Download PDF

Info

Publication number
CA2548038A1
CA2548038A1 CA002548038A CA2548038A CA2548038A1 CA 2548038 A1 CA2548038 A1 CA 2548038A1 CA 002548038 A CA002548038 A CA 002548038A CA 2548038 A CA2548038 A CA 2548038A CA 2548038 A1 CA2548038 A1 CA 2548038A1
Authority
CA
Canada
Prior art keywords
benzodiazepine
compound
ethyl
methyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002548038A
Other languages
English (en)
Inventor
Steven M. Leventer
Robert F. Kucharik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vela Acquisition Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/727,940 external-priority patent/US20040138209A1/en
Application filed by Individual filed Critical Individual
Publication of CA2548038A1 publication Critical patent/CA2548038A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I) dans laquelle R?1¿, R?2¿, R?3¿, R?4¿, R?5¿ et n sont tels que définis dans la description. Ces composés sont administrés à un faible dosage aux fins de prévention ou de traitement de troubles inflammatoires, notamment des troubles des tissus épithéliaux, tels que ceux de la peau et du tractus gastro-intestinal.
CA002548038A 2003-12-03 2004-12-03 Traitement de troubles inflammatoires de l'epithelium au moyen de 2,3-benzodiazepines en faible dose Abandoned CA2548038A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
USPCT/US03/38643 2003-12-03
US10/727,940 2003-12-03
US10/727,940 US20040138209A1 (en) 2002-12-03 2003-12-03 Treatment of inflammatory disorders with 2,3- benzodiazepines
PCT/US2003/038643 WO2004050080A1 (fr) 2002-12-03 2003-12-03 Traitement de troubles inflammatoires par des 2,3-benzodiazepines
PCT/US2004/040403 WO2005056017A1 (fr) 2003-12-03 2004-12-03 Traitement de troubles inflammatoires de l'epithelium au moyen de 2,3-benzodiazepines en faible dose

Publications (1)

Publication Number Publication Date
CA2548038A1 true CA2548038A1 (fr) 2005-06-23

Family

ID=34680839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002548038A Abandoned CA2548038A1 (fr) 2003-12-03 2004-12-03 Traitement de troubles inflammatoires de l'epithelium au moyen de 2,3-benzodiazepines en faible dose

Country Status (4)

Country Link
EP (1) EP1689408A4 (fr)
JP (1) JP2007513171A (fr)
CA (1) CA2548038A1 (fr)
WO (1) WO2005056017A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1124556T3 (da) * 1998-10-27 2004-10-11 Vela Pharmaceuticals Inc Anvendelse af optisk rent (R)-tofisopam til behandling og forebyggelse af angstsygdomme
US6080736A (en) * 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
FR2824065A1 (fr) * 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

Also Published As

Publication number Publication date
EP1689408A4 (fr) 2010-03-03
WO2005056017A1 (fr) 2005-06-23
JP2007513171A (ja) 2007-05-24
EP1689408A1 (fr) 2006-08-16

Similar Documents

Publication Publication Date Title
CA2508312C (fr) Traitement de troubles inflammatoires par des 2,3-benzodiazepines
US7745431B2 (en) Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof
KR101224262B1 (ko) 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
JP2003526594A (ja) カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
WO2010054114A2 (fr) Antagonistes cycloalcane[b]azaindoles de récepteurs de la prostaglandine d2
ITMI980146A1 (it) Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche
US20030069272A1 (en) Method of enhancing joint lubrication with nicotinic acetylcholine receptor agonists
US6638928B1 (en) Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
US20070032479A1 (en) Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
CA2525273C (fr) Traitement d'un dysfonctionnement gastro-intestinal et du stress associe au moyen d'une (r) 2,3-benzodiazepine pure sur le plan enantiomere
US20040152695A1 (en) Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof
CA2548038A1 (fr) Traitement de troubles inflammatoires de l'epithelium au moyen de 2,3-benzodiazepines en faible dose
US7022700B2 (en) Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
JP2002504134A (ja) 疼痛を治療するためのドラフラジン類似体の使用
CA2083611A1 (fr) Utilisation d'antagonistes du facteur d'activation des plaquettes comme agents antiprurigineux
US9408852B2 (en) Method of lowering serum uric acid levels with (S)-tofisopam
CN106265677B (zh) 一种防治溃疡性结肠炎的药物组合物及其应用
CN112755192A (zh) 双环醇类化合物在制备用于预防或治疗动脉粥样硬化疾病的药物中的应用和药物组合物
WO2014171740A1 (fr) Composition pharmaceutique pour traiter ou soulager l'arthrite, contenant de l'acéclofénac ou un sel de qualité pharmaceutique de celui-ci, et extrait comportant de la clematis florida, de la paeonia lactiflora pall. et de la var. lilacina nakai de brunelle commune

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20101203